Search

Search Constraints

You searched for: Author/Creator Ezekowitz, Michael D.

Search Results

1. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Issue 2 (9th July 2019)

2. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial. Issue 2 (22nd January 2019)

4. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Issue 8 (23rd August 2016)

5. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. (1st October 2015)

6. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial. (September 2013)

7. Drug Interactions Affecting Oral Anticoagulant Use. (27th May 2022)

8. Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Issue 6 (25th November 2013)

9. Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. Issue 9 (1st September 2015)

10. Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. Issue 9 (1st September 2015)